This paper describes the technical and analytical performance of a novel set of hybridization probes for the four GARDASIL ® vaccinerelevant HPV types (6, 11, 16 and 18). These probes are obtained through in vitro selection from a pool of random oligonucleotides, rather than the traditional "rational design" approach typically used as the initial step in assay development. The type-specific segment of the HPV genome was amplified using a GP5 + /6 + PCR protocol and 39 synthetic oligonucleotide templates derived from each of the HPV types, as PCR targets. The robust performance of the 4 selected hybridization probes was demonstrated by monitoring the preservation of the specificity and sensitivity of the typing assay over all 39 HPV types, using a different spectrum of HPV (genome equivalent: 10 3 -10 9 ) and human DNA concentrations (10-100 ng) as well as temperature and buffer composition variations. To the Authors' knowledge, this is a unique hybridization-based multiplex typing assay. It performs at ambient temperatures, does not require the strict temperature control of hybridization conditions, and is functional with a number of different non-denaturing buffers, thereby offering downstream compatibility with a variety of detection methods. Studies aimed at demonstrating clinical performance are needed to validate the applicability of this strategy.
Introduction
The HPV vaccination era calls for new standards for HPV screening programs. [1] [2] [3] National public health institutions require the monitoring of vaccine efficacy and HPV typing has become clinically and epidemiologically relevant. Two HPV diagnostic assays have been approved by the US Food and Drug Administration (Hybrid Capture 2, HC-2, Qiagen and Cervista HPV 16/18 genotyping tests, Hologic, Beford, Mass., USA), while Linear Array HPV genotyping test (Roche) and INNO-LiPA HPV Genotyping v2 (Innogenetics) assay are registered for use in the European Union. They are followed by a spectrum of other assays in late development and early validation phases. [4] [5] [6] These assays demand sophisticated instrumentation, significant material cost outlays and technically-skilled personnel. Concor dance among various assays under certain conditions (e.g. mixed infections) still needs to be technically resolved. 7, 8 The next generation of HPV typing assays (bead-based platforms) are in the developmental phase (for research purposes only) and although they have a higher throughput capacity and elegant design, their overall assay cost represents a heavy burden for national health care screening programs. [9] [10] [11] [12] [13] [14] [15] Of additional concern is that most of the world's population does not have access to the equipment required to perform current HPV typing procedures. 16 Encouraging efforts have been made by PATH-QIAGEN to introduce screening assays to developing countries. 17 However, a robust typing assay still does not exist. At the heart of this problem is a dominant technological and scientific hurdle imposed by the current limited understanding of the specificity of nucleic acid interactions.
A recently described technique [18] [19] [20] was applied to bring HPV typing one step closer to robust performance. The technique uses in vitro selection procedures to generate oligonucleotide probes with type-specific resolution. Hybridization probes, empirically obtained through selection, are used to build a novel hybridization assay that is applicable to a number of different platforms. The assay uses welldescribed GP5 + /6 + HPV PCR 21, 22 with minor modifications. 19 After amplicon conversion to the single stranded form, hybridization with type-specific probes is performed. Assay performance is further analytically tested under varying conditions: a different HPV copy number within the context of human DNA and a range of temperatures under which robust hybridization and washing may typically be performed. To the Authors' knowledge, this is a unique hybridization-based multiplex typing assay that does not require temperature-controlled hybridization conditions. Due to the inherent features of selected probes, the hybridization assay is operative within different (non-denaturing) buffers. That feature might provide downstream compatibility with a number of different detection techniques.
In this work we hypostatize that: (a) selected probes 19 do have robust performance (tolerate 8-10°C operative range) and preserve analytical sensitivity of 1,000 genome equivalents of HPV in the context of 10,000 (or less) of human genome equivalents; and (b) selected probes preserved specificity over the same conditions as in (a) for a specific target (either 6, or 11, or 16, or 18) and did not show any cross-hybridization with any of the remainder 38 HPV types, for which counterselection was performed.
Materials and Methods

Oligonucleotides
The oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, Iowa, USA). Targets were 139-148 nucleotide-long, type-specific segments (GP5 + strands) of GP5 + /6 + amplicons, located between positions 6624 and 6765 of the HPV16 sequence (accession number K02718). The 5' block TTC-GACAGGAGGCTCACAACAGGC and 3' block TGGGAGACAAGAATA AACGCTCAA were used to "block" the anchoring segments of the probes. The forward GP5 + primer has been previously described 20 and a mixture of 4 oligonucleotides was used as a reverse GP6+ primer: 
G A A A A A T A A A C T G T A A A T C A T A T T C , G A A A A A T A A A C T G T A A A T C A T A C T C , GAAAAATAAACTGTAAATCAAATTC
and GAAAAATAAACTGTAAATCAAACTC. 19 The universal HPV probe (UP) sequence was: GAAAAATAAACTGTAAATCATATTCCTCCACAT-GTCTTATATATTCCTTAAA. All type-specific probes were obtained using an in vitro selection procedure (Figure 1 ). The selected probes used in this assay were: i) for HPV 6: 5'GCCT-GTTGTGAGCCTCCTGTCGAAGGAAGATGTAG-GTAGGGATCGA TTGAGCGTTTATTCTTGTCTC-CCA3'; ii) for HPV11: 5'GCCTGTTGTGAGCCTC-CTGTCGAATTAGTGTATGTAGCATGCGACA TTGAGCGTTTATTCTTGTCTCCCA3'; iii) for HPV16: 5'GCCTGTTGTGAGCCTCCTGTCGAA GATCGGGAAGTAGATATGGCGC TTGAGCGTT-TATTCTTGTCTCCCA3'; iv) for HPV 18: 5'GC-CTGTTGTGAGCCTCCTGTCGAA GAGACAGGTA-GAAGGGCCCAGG TTGAGCGTTTATTCTTGTCT CCCA3'.
DNA extraction
Human DNA used for spiking experiments was extracted from blood (QIAamp DNA tubes, Qiagen, Mississauga, Ont., Canada), while the concentration was measured using NanoDrop (NanoDrop ND-1000, Wilmington, Del., USA) and DNA integrity was validated on 0.7% agarose gel.
PCR
The 50 mL-volume PCR was performed as originally suggested 20 with minor modifications including shortening the elongation and denaturation time to 20 sec. This modification was applied to minimize non-specific amplification, which was present in the original protocol, 20 especially in the cases where the copy number of HPV targets was below 1,000 HPV viral copies in the context of 1,000 or more genome copies of human DNA. PCR yield was monitored by loading a 10 mL reaction mix on 1.5% agarose gel and EtBr staining.
Conversion of PCR product to single-stranded (ss) DNA and labeling
The rest of the PCR mix (40 mL) was digested for 15 min at 37°C with Exonuclease I (New England Biolabs Ltd., Pickering, Ont., Canada) to remove excess primers following enzyme inactivation (20 min, 85°C). Lambda exonuclease (New England Biolabs Ltd., Pickering, Canada) was used (15 min, 37°C) to remove a GP6 + PCR strand, followed by an enzyme inactivation step (20 min, 85°C). The sample was passed through a Sephadex G-25 (GE Healthcare Life Science, Baie d'Urfé, Quebec, Canada) for buffer exchange reaction compatibility with a downstream T4 polynucleotide kinase (Invitrogen, Burlington, Ont., Canada) labeling step.
Membrane
Streptavidine-coated Promega membrane (SAM, Biotin Capture Membrane, Medison, Wisc., USA) was used in the following manner. One mL of 100 pmol/mL of type-specific 5' biotinilated oligonucleotide probes was manually spotted (HPV6, HPV11, HPV 16 and HPV 18) on the surface of a 3¥2 cm membrane (see Figure  2 for spotting schematic). The 0.3 pmol of the HPV universal probe (UP) was spotted on the membrane and dried at ambient temperature for 5 min. The membrane was washed in H 2 O for 1-2 min and pre-hybridized in 2 mL hybridization buffer: SSPE (150 mM NaCl, 10 mM NaH 2 PO 4 , 1.1 mM EDTA, pH 7.4), containing 1% SDS and 200 mg/mL heparin (hybridization oven, Model 400, Robbins Scientific) for 1-12 h at 55°C. The membrane was either stored at room temperature (for as long as four days) or immediately used for hybridization assay.
Labeling
Labeling (SA, specific activity of 10 5 -10 6 cpm/pmol) of 2-20 pmol of single-stranded PCR product and/or an oligonucleotide was performed using 5 mL of [g-32P] ATP (6000 Ci/mmol) and 1 mL of T4 polynucleotide kinase, following the manufacturer's recommendations (Invitrogen, Burlington, Ont., Canada).
Hybridization
Hybridization was carried out in the hybridization buffer for 1-12 h, at ambient temperatures (22±2°C). To analyze the effect of temperature variation, hybridization was also carried out at fixed temperatures ( Figure 3) . The membrane was washed with hybridization buffer containing 0.1% SDS for 10 min at ambient temperature and either exposed overnight at -80°C with intensifying screens or exposed in Cyclone Storage Phosphore Screen (Perkin Elmer Life and Analytical Sciences, Shelton, Conn., USA) for 10-30 min and read by Cyclone software (OptiQuant, version 4.00, Packard Instrument Co., Boston, Mass., USA).
Results
The performance of a new generation of HPV-type specific hybridization probes is presented. They were obtained using in vitro selection as opposed to rational and computerassisted in silico design and optimization. A set of such probes for 39 HPV types has been previously obtained. 19 Briefly, selection from the random pool of probes was composed of 5 preparative hybridization steps (Figure 1 , Steps 1 to 3) using the intended type-specific HPV target, followed by 3 subtractive hybridization steps (Figure 1 , Steps 4 to 6). During subtractive steps, the remaining 38 non-intended targets were added into the hybridization mix. The selected probes were cloned, sequenced, chemically synthesized and tested for their specificity. 19 Here, the focus was on 4 vaccinerelevant HPV-types. The assay format, including the 4 corresponding probes, was dictated by its clinical relevance and expected costeffectiveness.
The experiments were performed to test the limits of the specificity, sensitivity and robustness of the assay. First, the specificity of hybridization probes was tested under conditions where the concentration of targets was about 10 times higher than that of the typical PCR yield. All probes were hybridized in the presence of 20 pmol of all 39 HPV type-specific single-stranded oligonucleotides, identical to a GP5 + primed single strand of double stranded PCR. Our typical PCR yield does not exceed 1 mg of product (from 50 mL reaction mixture). Therefore, maximal number of post-PCR molecules is lower then tens of picomols. Tested probes were hybridized with 20 pmols of each of the 39 type-specific amplicons (synthetic oligonucleotides) and neither (except intended targets) gave any detectable signal. The fact that there was no observed cross-hybridization even in an extremely high concentration of HPV amplicons, indicates high specificity of the selected probes.
Second, the sensitivity of the assay was tested using PCR amplified targets in the context of 10 and 100 ng of human DNA (Figure 2 ) approximating clinical samples in the range of 10 3 -10 4 human genome equivalents. While estimating assay sensitivity, we used terminology of minimal numbers of required genome equivalents per reaction mix. This term would be equivalent to the viral copy numbers per assay, without refereeing to the assay volume units. Viral loads reflecting 100 and 10,000 copy numbers of HPV were analyzed in the context of variable genome-equivalents of human DNA (Figure 2A-C) . For example, samples having 10:1 and 1:1 ratios between HPV and human genome equivalents produced clear patterns (Figure 2 A and B) . However, a 1:10 ratio between HPV and human genome copies produced noise in the hybridization patterns ( Figure 2C ). The 100 copies of HPV in the context of 1,000 human genome equivalents were not amplified well enough to be detected. These results reflect the present limits of assay sensitivity, which are related to the present limits of PCR sensitivity.
Clinical samples, which were previously genotyped by RFLP analysis using the MY 09/MY 11 primer set, were analyzed (Figure 2  D) . RFLP vs. hybridization assay produced the same typing data when single infections were considered. When multiple infections were simulated (equimolar quantities of 2-4 targets), the PCR amplified oligonucleotide targets produced type-specific signals of uneven intensity (data not shown). However, when hybridization was carried out without intermediate PCR amplification, the hybridization patterns were proportional to the concentration of input multiple target templates (again equimolar quantities of 2-4 targets). A similar observation has recently been noted with clinical samples: mixed infections produced highly disconcordant typing results among a variety of assays. 8 To evaluate the robustness of the assay, hybridization was carried out at different temperatures in the range of 20-35°C (Figure 3) . The hybridization buffer was changed from the one previously used 19 for the selection of HPV typing probes (10 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 and 50 mM NaCl) to the one described in the Methods section in order to better fit the membrane-based hybridization requirements.
Discussion
HPV typing using multiplex hybridization assays is facing two distinct technical issues. The first one concerns cross-hybridization among non-intended targets. As shown by the present evaluation of the sensitivity, specificity and robustness of our HPV typing assay to detect 4 GARDASIL ® -relevant HPV types (6, 11, 16 and 18) , this issue was successfully resolved. The second technical issue is more general: an amplification bias caused by the use of a variety of different PCR-based "broadrange" primer sets. The roots of both problems, stemmed from an insufficient knowledge of sequence-dependent interactions among nucleic acids. The second technical problem caused significant non-concordance among different typing assays, when reporting double or multiple HPV infections, "probably due to the differences in the affinities of the primer sets for the different HPV types". 8 Therefore, clinical validations of a range of primer designs 14 and improved amplification procedures or pre-PCR sample enrichments 12 are necessary.
The 4 selected probes (6,11,16 and 18) were tested against 39 different HPV types under defined conditions (presented as hypotheses (a); see above). Only intended target sequences showed hybridization signal, while the rest of non-intended targets did not show any detectable cross-hybridization. The signal had a minimum 10 times stronger P 32 number of counts per minutes than background, over the same membrane surface. The visual presentation of autoradiography of membranes (Figures 2 and 3 ed and spotted probes, which is in agreement with our fluorescence assay presented in a previous work. 19 The 100 copies of HPV in the context of 1,000 GE of human DNA was difficult to detected (signal -noise ration lower than 10), while 1,000 HPV copies were clearly detected for all types. The current sensitivity of the assay described herein is comparable with the lower limits of detection of FDA-approved HC-2 (1,000 copies of HPV). However, one should note that sensitivity can be increased by: i) changing the original GP5 + /6 + PCR conditions; ii) using newer primer sets described in the literature 14 re-designing new primer sets. This assay was tested at 4 hybridization temperatures (20°C, 25°C, 30°C and 35°C) (Figure 3) . While hybridization intensity increased with decreasing temperature, the assay specificity was preserved over this range of temperature conditions. This feature is advantageous when compared with other commercial HPV typing assays where small variations of 1-2ºC lead to cross-hybridization or loss of sensitivity. 23, 24 The assay performance was well tolerated using 2 different hybridization buffers. This inherent feature of selected probes is important, considering different buffer requirements of enzyme-driven colorimetric reactions that could eventually be applied here to detect a specific hybridization event.
The attractive use of this type of assay in clinical practice would be isothermal amplification (Biohelix, US) combined with chromatographic hybridization detection (ChemBio Diagnostics), offering a hands off, instruments off, simple, multiplex, point-ofcare diagnostic test.
It is clear that the current form of the assay would need to address a combination of add tional optimization factors to achieve required sensitivity, while switching from P 32 to colorimetric, or fluoromoetric detection.
The technique of the in vitro selection of oligonucleotides of diagnostic and therapeutic value was introduced in 1990 by Tuerk, Gold, Ellington and Szostak. 25, 26 The demonstrated robustness of hybridization probes under various "environmental conditions" represents an unexpected result. It seems that selection-captured molecular determinants in probe-target complexes are only those that are consistently preserved under imposed conditions of selection. This feature is very useful and should encourage the development of a fast and automatic generation of diagnostic probes.
Based on the overall results, it can be concluded that the in vitro selection of hybridization probes is a valuable technological choice for engineering multiplex robust point-of-care diagnostic assays. Further studies aimed at avoiding amplification bias are needed to illustrate the universal clinical applicability of these types of molecular detection assay.
